Molecular mechanisms of the chemopreventive effect on hepatocellular carcinoma development in Mdr2 knockout mice

Molecular Cancer Therapeutics

Volumn 6, Issue 4, 2007, Pages 1283-1291

  Katzenellenbogen, Mark ^a   Mizrahi, Lina ^a   Pappo, Orit ^a   Klopstock, Naama ^a   Olam, Devorah ^a   Barash, Hila ^a   Domany, Eytan ^b   Galun, Eithan ^a   Goldenberg, Daniel ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; COMPLEMENTARY DNA; SELENIUM; SELENOMETHIONINE; TANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA PROBE; DRUG MECHANISM; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; INFLAMMATION; KNOCKOUT MOUSE; LIPID METABOLISM; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY MECHANISM; TUMOR VOLUME; UPREGULATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; GENE EXPRESSION PROFILING; LIVER; LIVER NEOPLASMS; MICE; MICE, KNOCKOUT; P-GLYCOPROTEINS; PRECANCEROUS CONDITIONS; PROLIFERATING CELL NUCLEAR ANTIGEN; SELENOMETHIONINE; TANNINS;

EID: 34248151975     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0420     Document Type: Article

References (49)

1. Balmain A, Harris CC. Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis 2000;21:371-7.
2. Fausto N. Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin Liver Dis 1999;19:243-52.
3. Thorgeirsson SS, Factor VM, Snyderwine EG. Transgenic mouse models in carcinogenesis research and testing. Toxicol Lett 2000;112-3:553-5.
4. Lee JS, Chu IS, Mikaelyan A, et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 2004;36:1306-11.
5. Mauad TH, van Nieuwkerk CM, Dingemans KP, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994;145:1237-45.
6. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-6.
7. Katzenellenbogen M, Pappo O, Barash H, et al. Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. Cancer Res 2006;66: 4001-10.
8. Smit JJ, Schinkel AH, Oude Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451-62.
9. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004;127:261-74.
10. Factor VM, Laskowska D, Jensen MR, Woitach JT, Popescu NC, Thorgeirsson SS. Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. Proc Natl Acad Sci U S A 2000;97:2196-201.
11. Popova NV. Perinatal selenium exposure decreases spontaneous liver tumorogenesis in CBA mice. Cancer Lett 2002;179:39-42.
12. Novoselov SV, Calvisi DF, Labunskyy VM, et al. Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene 2005;24:8003-11.
13. Nepka C, Sivridis E, Antonoglou O, et al. Chemopreventive activity of very low dose dietary tannic acid administration in hepatoma bearing C3H male mice. Cancer Lett 1999;141:57-62.
14. Marienfeld C, Tadlock L, Yamagiwa Y, Patel T. Inhibition of cholangiocarcinoma growth by tannic acid. Hepatology 2003;37: 1097-104.
15. 1 arrest and apoptosis. Cancer Epidemiol Biomarkers Prev 2001;10: 1083-8.
16. Chen X, Beutler JA, McCloud TG, et al. Tannic acid is an inhibitor of CXCL12 (SDF-1alpha)/CXCR4 with antiangiogenic activity. Clin Cancer Res 2003;9:3115-23.
17. Srivastava RC, Husain MM, Hasan SK, Athar M. Green tea polyphenols and tannic acid act as potent inhibitors of phorbol ester-induced nitric oxide generation in rat hepatocytes independent of their antioxidant properties. Cancer Lett 2000;153:1-5.
18. Taitzoglou IA, Tsantarliotou MP, Nepka C, et al. Dietary administration of tannic acid lowers plasminogen activator activity in the liver of C3H hepatoma bearing male mice. In Vivo 2000;14:767-71.
19. Whanger PD. Selenium and its relationship to cancer: an update dagger. Br J Nutr 2004;91:11-28.
20. Ip C, Dong Y, Ganther HE. New concepts in selenium chemoprevention. Cancer Metastasis Rev 2002;21:281-9.
21. El-Bayoumy K, Sinha R. Molecular chemoprevention by selenium: a genomic approach. Mutat Res 2005;591:224-36.
22. Wootton JC, Federhen S. Analysis of compositionally biased regions in sequence databases. Methods Enzymol 1996;266:554-71.
23. Wheeler DL, Church DM, Lash AE, et al. Database resources of the National Center for Biotechnology Information: 2002 update. Nucleic Acids Res 2002;30:13-6.
24. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, editors. Bioinformatics methods and protocols: methods in molecular biology. Totowa (NJ): Humana Press; 2000. p. 365-86.
25. Wang SM, Fears SC, Zhang L, Chen JJ, Rowley JD. Screening poly(dA/dT)- cDNAs for gene identification. Proc Natl Acad Sci U S A 2000;97:4162-7.
26. Tsafrir D, Tsafrir I, Ein-Dor L, Zuk O, Notterman DA, Domany E. Sorting points into neighborhoods (SPIN): data analysis and visualization by ordering distance matrices. Bioinformatics 2005;21:2301-8.
27. Bo T, Jonassen I. New feature subset selection procedures for classification of expression profiles. Genome Biol 2002;3:RESEARCH0017.
28. Seifried HE, McDonald SS, Anderson DE, Greenwald P, Milner JA. The antioxidant conundrum in cancer. Cancer Res 2003;63:4295-8.
29. Oberley TD. Oxidative damage and cancer. Am J Pathol 2002;160: 403-8.
30. Mantovani G, Maccio A, Madeddu C, et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer 2002;98:84-91.
31. Halliwell B. Effect of diet on cancer development: is oxidative DNA damage a biomarker? Free Radic Biol Med 2002;32:968-74.
32. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004;44:239-67.
33. Li J, Lee JM, Johnson DA, Johnson JA. Antioxidant responsive element activation by quinones: antioxidant responsive element target genes, role of PI3 kinase in activation. Methods Enzymol 2004;378:238-58.
34. Brash DE, Havre PA. New careers for antioxidants. Proc Natl Acad Sci U S A 2002;99:13969-71.
35. Owuor ED, Kong AN. Antioxidants and oxidants regulated signal transduction pathways. Biochem Pharmacol 2002;64:765-70.
36. Hayes JD, McMahon M. Molecular basis for the contribution of the antioxidant responsive element to cancer chemoprevention. Cancer Lett 2001;174:103-13.
37. Kwak MK, Itoh K, Yamamoto M, Kensler TW. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol Cell Biol 2002;22:2883-92.
38. Mukhopadhyay-Sardar S, Rana MP, Chatterjee M. Antioxidant associated chemoprevention by selenomethionine in murine tumor model. Mol Cell Biochem 2000;206:17-25.
39. Van Molle W, Vanden Berghe J, Brouckaert P, Libert C. Tumor necrosis factor-induced lethal hepatitis: pharmacological intervention with verapamil, tannic acid, picotamide and K76COOH. FEBS Lett 2000;467:201-5.
40. Ma Q, Kinneer K, Ye J, Chen BJ. Inhibition of nuclear factor kappaB by phenolic antioxidants: interplay between antioxidant signaling and inflammatory cytokine expression. Mol Pharmacol 2003;64:211-9.
41. Zu K, Ip C. Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res 2003;63:6988-95.
42. Lu J, Jiang C. Antiangiogenic activity of selenium in cancer chemoprevention: metabolite-specific effects. Nutr Cancer 2001;40: 64-73.
43. Seo YR, Kelley MR, Smith ML. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci U S A 2002;99: 14548-53.
44. Smith ML, Lancia JK, Mercer TI, Ip C. Selenium compounds regulate p53 by common and distinctive mechanisms. Anticancer Res 2004;24: 1401-8.
45. Gasparian AV, Yao YJ, Lu J, et al. Selenium compounds inhibit I kappa B kinase (IKK) and nuclear factor-kappa B (NF-kappa B) in prostate cancer cells. Mol Cancer Ther 2002;1:1079-87.
46. Kim SH, Johnson VJ, Shin TY, Sharma RP. Selenium attenuates lipopolysaccharide-induced oxidative stress responses through modulation of p38 MAPK and NF-kappaB signaling pathways. Exp Biol Med (Maywood) 2004;229:203-13.
47. Saito Y, Yoshida Y, Akazawa T, Takahashi K, Niki E. Cell death caused by selenium deficiency and protective effect of antioxidants. J Biol Chem 2003;278:39428-34.
48. Irmak MB, Ince G, Ozturk M, Cetin-Atalay R. Acquired tolerance of hepatocellular carcinoma cells to selenium deficiency: a selective survival mechanism? Cancer Res 2003;63:6707-15.
49. van Nieuwerk CM, Groen AK, Ottenhoff R, et al. The role of bile salt composition in liver pathology of mdr2 (-/-) mice: differences between males and females. J Hepatol 1997;26:138-45.